S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
All the trading advice you’ve ever received boils down to this (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
As Dollar Tree Goes, So Goes the Consumer?
Power Play: GE's game-changing technology for EVs and grids
Why Microsoft Just Placed A Huge Bet On Nuclear (Ad)
Is Beyond an overlooked e-commerce winner?
Inflation in Europe falls to 2.4% as interest rates pack a punch. But the economy has stalled
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
All the trading advice you’ve ever received boils down to this (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
As Dollar Tree Goes, So Goes the Consumer?
Power Play: GE's game-changing technology for EVs and grids
Why Microsoft Just Placed A Huge Bet On Nuclear (Ad)
Is Beyond an overlooked e-commerce winner?
Inflation in Europe falls to 2.4% as interest rates pack a punch. But the economy has stalled
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
All the trading advice you’ve ever received boils down to this (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
As Dollar Tree Goes, So Goes the Consumer?
Power Play: GE's game-changing technology for EVs and grids
Why Microsoft Just Placed A Huge Bet On Nuclear (Ad)
Is Beyond an overlooked e-commerce winner?
Inflation in Europe falls to 2.4% as interest rates pack a punch. But the economy has stalled
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
All the trading advice you’ve ever received boils down to this (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
As Dollar Tree Goes, So Goes the Consumer?
Power Play: GE's game-changing technology for EVs and grids
Why Microsoft Just Placed A Huge Bet On Nuclear (Ad)
Is Beyond an overlooked e-commerce winner?
Inflation in Europe falls to 2.4% as interest rates pack a punch. But the economy has stalled

Corbus Pharmaceuticals Stock Price, News & Analysis (NASDAQ:CRBP)

$6.69
+1.84 (+37.94%)
(As of 11/30/2023 ET)
Compare
Today's Range
$4.76
$6.69
50-Day Range
$3.16
$6.80
52-Week Range
$2.11
$13.17
Volume
46,973 shs
Average Volume
144,066 shs
Market Capitalization
$29.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.50

Corbus Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
86.8% Upside
$12.50 Price Target
Short Interest
Bearish
1.29% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.65
Upright™ Environmental Score
News Sentiment
0.63mentions of Corbus Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($11.00) to ($6.59) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.04 out of 5 stars

Medical Sector

567th out of 949 stocks

Pharmaceutical Preparations Industry

262nd out of 435 stocks


CRBP stock logo

About Corbus Pharmaceuticals Stock (NASDAQ:CRBP)

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, an endocannabinoid small molecule drug for the treatment of obesity and related metabolic diseases; and lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial or the treatment of inflammation and fibrosis. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

CRBP Stock Price History

CRBP Stock News Headlines

Corbus Pharmaceuticals Holding (0SZI)
The Only Practical Solution to the World’s Looming Energy Crisis
There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!
The Only Practical Solution to the World’s Looming Energy Crisis
There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!
CRBP - Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals (NASDAQ: CRBP)
See More Headlines
Receive CRBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corbus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
11/30/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/05/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRBP
Employees
33
Year Founded
2009

Price Target and Rating

Average Stock Price Target
$12.50
High Stock Price Target
$22.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+131.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-42,350,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$880,000.00
Book Value
$0.07 per share

Miscellaneous

Free Float
4,123,000
Market Cap
$23.87 million
Optionable
Optionable
Beta
2.33

Social Links

The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Dr. Yuval Cohen Ph.D. (Age 48)
    CEO & Director
    Comp: $890.67k
  • Mr. Sean F. Moran CPA (Age 65)
    M.B.A., Chief Financial Officer
    Comp: $579.05k
  • Dr. Rachael Brake Ph.D. (Age 51)
    Chief Scientific Officer
    Comp: $552.22k
  • Ted Jenkins
    Senior Director of Investor Relations & Corporate Communications
  • Ms. Lindsey Smith
    Head of Corporate Communications & Patient Advocacy
  • Ms. Christina Bertsch
    Head of Human Resources














CRBP Stock Analysis - Frequently Asked Questions

Should I buy or sell Corbus Pharmaceuticals stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CRBP shares.
View CRBP analyst ratings
or view top-rated stocks.

What is Corbus Pharmaceuticals' stock price target for 2024?

2 Wall Street analysts have issued 12-month price targets for Corbus Pharmaceuticals' shares. Their CRBP share price targets range from $3.00 to $22.00. On average, they anticipate the company's stock price to reach $12.50 in the next year. This suggests a possible upside of 86.8% from the stock's current price.
View analysts price targets for CRBP
or view top-rated stocks among Wall Street analysts.

How have CRBP shares performed in 2023?

Corbus Pharmaceuticals' stock was trading at $0.1105 at the start of the year. Since then, CRBP stock has increased by 5,954.3% and is now trading at $6.69.
View the best growth stocks for 2023 here
.

When is Corbus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 5th 2024.
View our CRBP earnings forecast
.

How were Corbus Pharmaceuticals' earnings last quarter?

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) announced its quarterly earnings results on Tuesday, November, 7th. The biopharmaceutical company reported ($2.27) earnings per share for the quarter, missing the consensus estimate of ($2.06) by $0.21.

What other stocks do shareholders of Corbus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO) and KushCo (KSHB).

Who are Corbus Pharmaceuticals' major shareholders?

Corbus Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Craig Stuart Millian, Sean F Moran and Yuval Cohen.
View institutional ownership trends
.

How do I buy shares of Corbus Pharmaceuticals?

Shares of CRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CRBP) was last updated on 12/1/2023 by MarketBeat.com Staff

My Account -